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Abstract
Background Open abdomen (OA) may be required in patients with abdominal trauma, sepsis or compartment syndrome. 
Vacuum-assisted wound closure and mesh-mediated fascial traction (VAWCM) is a widely used approach for temporary 
abdominal closure to close the abdominal wall. However, this method is associated with a high incidence of re-operations 
in short term and late sequelae such as incisional hernia. The current study aims to compare the results of surgical strategies 
of OA with versus without permanent mesh augmentation.
Methods Patients with OA treatment undergoing vacuum-assisted wound closure and an intraperitoneal onlay mesh (VAC-
IPOM) implantation were compared to VAWCM with direct fascial closure which represents the current standard of care. 
Outcomes of patients from two tertiary referral centers that performed the different strategies for abdominal closure after 
OA treatment were compared in univariate and multivariate regression analysis.
Results A total of 139 patients were included in the study. Of these, 50 (36.0%) patients underwent VAC-IPOM and 89 
(64.0%) patients VAWCM. VAC-IPOM was associated with reduced re-operations (adjusted incidence risk ratio 0.48 per 
10-person days; CI 95% = 0.39–0.58, p < 0.001), reduced duration of stay on intensive care unit (ICU) [adjusted hazard 
ratio (aHR) 0.53; CI 95% = 0.36–0.79, p = 0.002] and reduced hospital stay (aHR 0.61; CI 95% = 0.040–0.94; p = 0.024). 
In-hospital mortality [22.5 vs 18.0%, risk difference − 4.5; confidence interval (CI) 95% = − 18.2 to 9.3; p = 0.665] and the 
incidence of intestinal fistula (18.0 vs 22.0%, risk difference 4.0; CI 95% = −10.0 to 18.0; p = 0.656) did not differ between 
the two groups. In Kaplan–Meier analysis, hernia-free survival was significantly increased after VAC-IPOM (p = 0.041).
Conclusions In patients undergoing OA treatment, intraperitoneal mesh augmentation is associated with a significantly 
decreased number of re-operations, duration of hospital and ICU stay and incidence of incisional hernias when compared 
to VAWCM.
Keywords Open abdomen · Vacuum-assisted wound closure and mesh-mediated fascial traction · Mesh augmentation · 
Non-absorbable mesh
Introduction
Open abdomen (OA) treatment with temporary abdominal 
closure using negative-pressure wound therapy has become 
a standard of care in trauma patients undergoing damage 
control surgery [1]. OA is also increasingly used in non-
trauma patients with abdominal sepsis or abdominal com-
partment syndrome as a life-saving procedure, especially in 
the growing older population with increased comorbidities 
and limited physiologic reserve [2].
Temporary abdominal closure needs to ensure the integ-
rity of the abdominal wall and to compartmentalize abdomi-
nal contents to avoid treatment-related complications (e.g., 
intestinal fistula, inability to close the abdominal wall). 
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Several methods for temporary abdominal closure have 
been described of which vacuum-assisted wound closure and 
mesh-mediated fascial traction (VAWCM) has been reported 
to be associated with the lowest fistula rate with high rates of 
fascial closure [3]. However, using the VAWCM technique, 
multiple surgical revisions are often required for definitive 
abdominal closure, which may lead to a prolonged ICU and 
total hospital duration of stay [4]. In addition, these patients 
exhibit a high rate of incisional hernias of up to 66% dur-
ing long-term follow-up potentially because of local fascial 
traction [5].
Therefore, novel strategies to support the abdominal wall 
in these patients are required. Synthetic mesh implantation 
has been shown to effectively support the abdominal wall 
[6]. However, the use of such meshes in OA may have been 
limited due to the lack of robust data and due to reports of 
mesh related complications [7]. We have previously shown 
that the use of synthetic meshes in patients with peritonitis 
or fascial dehiscence is an effective approach [8, 9]. Thus, a 
therapeutic algorithm that includes mesh-augmented defini-
tive abdominal closure (VAC-IPOM) in this severely ill 
patient’ population has been developed and introduced at the 
Bern University Hospital in 2005. The aim of this large two-
centre study was to compare this VAC-IPOM technique with 




All consecutive patients treated for OA between January 
2005 and December 2015 from two centers were analyzed. 
The participating centers were the Department for Visceral 
Surgery and Medicine, Bern University Hospital, Switzer-
land (patients with VAC-IPOM) and the Department for 
Surgery, Medical University of Vienna, General Hospi-
tal Vienna, Austria (patients with VAWCM). Patients not 
using the VAC-IPOM technique at the University Hospital 
of Bern (n = 22) were excluded from the study. Cantonal 
ethics committee of Bern, Switzerland and the institutional 
review board of the Medical University of Vienna, Austria 
have approved this study.
Outcome parameters
The primary outcome parameter was hernia-free survival. 
Secondary outcome parameters comprised of general com-
plications such as re-operations, duration of hospital stay, 
duration of stay on intensive care unit (ICU), mortality and 
mesh-associated complications such as intestinal fistula 
and surgical site infection (SSI). SSI infection was defined 
according to CDC criteria [10]. Intestinal fistula was defined 
as the persistent leakage of bowel contents within 100 days 
of the initial OA.
Surgical strategy
VAWCM group
OA was covered with abdominal dressings and dynamic 
tension on fascia was applied to avoid fascial retraction. 
Dynamic tension on fascia was applied either via vessel 
loops or temporary inlay meshes as previously described 
[11, 12]. The vessel loops were sutured to the anterior sheet 
of the rectus muscle and constant tension was applied to 
approximate the fascial edges. In addition, 18 (22.2%) 
patients received a temporary large-pore polypropylene inlay 
mesh. The mesh was sutured to the fascial edges with non-
absorbable sutures and was removed at definitive abdominal 
closure. The fasciae were closed with absorbable loops.
VAC-IPOM group
The technique has been previously published [13]. Briefly, 
patients with OA were treated for one or two cycles with 
abdominal dressings to stabilize the patients’ conditions. 
After this initial period, intraperitoneal onlay mesh implan-
tation was performed using dual-layered-, large pore, syn-
thetic meshes. Meshes were placed with an overlap of at 
least 5 cm on all sides. The meshes were fixed in all corners 
with a non-absorbable polypropylene suture  (Prolene®, Ethi-
con) and the edges were attached to the peritoneum with the 
same suture. The fascia was partially or completely closed 
with a PDS running suture  (PDS®, Ethicon). A vacuum 
dressing (V.A.C.®, KCI) was then placed on the mesh and 
continuous suction was applied (25–75 mmHg suction). 
Wound treatment included: (1) vacuum dressings until 
an adequate formation of granulation tissue was achieved 
and (2) skin re-adaptation with non-resorbable sutures 
 (Dermalon®, Covidien).
Statistical analysis
Data were reported as median and interquartile ranges (IQR), 
or numbers and percentages, as appropriate. Patients’ groups 
were compared using Fisher’s exact test and Mann–Whitney 
U test for categorical and continuous variables, respectively. 
Time-to-event outcomes were analysed using the log-rank 
test. Effects are reported as risk differences or c-statistics 
with 95% confidence intervals (CI). The primary endpoint 
hernia-free survival, was analyzed with Kaplan–Meier 
curves and a log-rank test for statistical comparison. The 
effect of mesh treatment on hernia-free survival and sec-
ondary outcomes was adjusted in multivariable regression 
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analyses. Clinically important and potential confounder 
variables (age, gender, BMI, emergency primary operation, 
malignancy, ASA score, immunosuppressive drugs) were 
tested in univariable models and included in the multivari-
able model if the p value was below 0.2. Logistic, Cox or 
Poisson regression were fitted for binary, time-to-event or 
count outcomes, respectively. Results were reported as odds 
ratio (OR), hazard ratio (HR) or incidence risk ratio (IRR) 
with 95% CI and p values. A two-sided p value of < 0.05 
was considered statistically significant. All statistical tests 
were performed using SPSS Statistics (Version 17.0.0, SPSS 
Inc., Chicago, IL).
Table 1  Patients’ characteristics
ASA American Society of Anaesthesiology, IQR interquartile range
VAWCM (n = 89) VAC-IPOM (n = 50) p
Age, median in years (IQR) 55 (48–67) 61 (55–72) 0.046
Male patients (%) 52 (58.4%) 30 (60.0%) 1.000
Body mass index in kg/m2 (IQR) 24.8 (21.0–29.2) 27.3 (23.1–35.0) 0.172
Known malignancy (%) 36 (41.8%) 27 (54.0%) 0.212
Type 2 diabetes (%) 15 (17.0%) 6 (12.0%) 0.471
Cardiac disease (%) 47 (52.8%) 23 (46.0%) 0.483
Pulmonary disease (%) 16 (18.0%) 20 (40.0%) 0.008
Liver disease (%) 18 (20.2%) 14 (28.0%) 0.303
Kidney disease (%) 20 (22.5%) 9 (18.0%) 0.665
Anticoagulation preoperative (%)
 Phenprocoumon 1 (1.2%) 5 (10.4%) 0.024
 Platelet aggregation inhibitors 5 (6.0%) 4 (8.3%) 0.723
 Dual anticoagulation 11 (13.1%) 2 (4.2%) 0.132
Immunosuppressors (%)
 Immunosuppressive drugs 1 (1.2%) 4 (8.2%) 0.090
 Cortisone 5 (6.2%) 2 (4.1%)
 Both 4 (4.9%) –
ASA score (%)
 2 35 (41.7%) 8 (16.3%) < 0.001
 3 43 (51.2%) 18 (36.7%)
 4 3 (3.6%) 22 (44.9%)
 5 3 (3.6%) 2 (4.1%)
Type of primary surgery (%)
 Hepatobiliary surgery 4 (4.5%) 1 (2.0%) 0.011
 Pancreatic surgery 6 (6.7%) –
 Upper GI surgery 14 (15.7%) 6 (12.0%)
 Resection of intestine with preserved continuity 23 (25.8%) 9 (18.0%)
 Resection of intestine without preserved continuity 19 (21.3%) 10 (20.0%)
 Pancreatic necrosectomy 3 (3.4%) –
 Multivisceral resections 4 (4.5%) 10 (20.0%)
 Vascular surgery 2 (2.2%) 4 (8.0%)
 Other 14 (15.7%) 10 (20.0%)
Emergency primary procedure (%) 41 (46.1%) 26 (52.0%) 0.596
Prior laparotomies, no. (IQR) 3 (1–4) 2 (1–3) 0.030
Duration of primary operation in minutes (IQR) 195 (135–318) 240 (163–300) 0.416
Incision at primary procedure (%)
 Median laparotomy 64 (75.3%) 49 (98.0%) 0.007
 Transverse Laparotomy 11 (12.9%) 1 (2.0%)
 Combined 9 (10.6%) –
 Laparoscopy 1 (1.2%) –
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Results
Meshes used in the VAC-IPOM group include polypropyl-
ene-based mesh in 39 (78%) patients, (Parietene  composite®, 
Medtronic, in 34 (87.2%) patients;  Dynamesh®, FEG Tex-
tiltechnik mbH, in 4 (10.3%) patients;  Vipro®, Ethicon, 
in 1 (2.5%) patient) and polyester-based meshes (Parietex 
 composite®, Medtronic) in 11 (22%) patients. Patients’ char-
acteristics are shown in Table 1.
Short‑term outcome
Detailed operative characteristics and postoperative results 
are shown in Table 2. There was no difference of the intesti-
nal fistula rate and in-hospital mortality between VAWCM 
and VAC-IPOM. The median number of re-operations 
after initiation of OA was 5 (IQR 2–13) for VAWCM and 
3 (IQR 2–5) for VAC-IPOM (Fig. 1). The incidence of re-
operations during hospitalisation per 10-person days after 
initiation of OA was 1.28 for VAWCM and 0.62 for VAC-
IPOM. Therefore, the adjusted incidence risk ratio for re-
operation was 0.48 for VAC-IPOM [95% confidence interval 
(CI), 0.39–0.58, p < 0.001] (Table 3). Duration of ICU stay 
was significantly longer for VAWCM compared to VAC-
IPOM [adjusted hazard ratio 0.53 (CI 95%, 0.36–0.79), 
p = 0.002] (Fig. 2a). Complete fascial closure was achieved 
in 66 (74.2%) patients for VAWCM versus 13 (26.0%) 
patients for VAC-IPOM [risk difference − 48.2 (CI 95%, 
− 63.3 to − 33.0), p < 0.001]. Duration of hospital stay was 
significantly longer for VAWCM compared to VAC-IPOM 
[adjusted hazard ratio 0.61 (CI 95%, 0.40–0.94), p = 0.024] 
(Fig. 2b).
Long‑term outcome
Median follow-up was 681 days (311–1091) for VAWCM 
and 426 (178–1058) for VAC-IPOM (p = 0.201). SSI at 
last follow-up was found in 3 patients for VAWCM [after a 
Table 2  Operative and postoperative results
IQR interquartile range, OA open abdomen, SSI surgical site infection
A Other included: a death due to brain oedema (n = 1), pulmonary embolism (n = 1), perforation of aorta (n = 1) and bdeath due to liver failure 
(n = 1)
VAWCM (n = 89) VAC-IPOM (n = 50) Effect measure (95% CI) p
Occurrence of OA after primary surgery in days (IQR) 11 (4–16) 11 (7–17) 0.53 (0.43 to 0.63) 0.605
Leakage of gastric anastomosis (%) 5 (5.6%) 1 (2.0%) − 3.6 (− 9.8 to 2.5) 0.419
Leakage of small intestinal anastomosis (%) 12 (13.5%) 9 (18.0%) 4.5 (− 8.3 to 17.3) 0.471
Leakage of colonic anastomosis (%) 3 (3.4%) 5 (10.0%) 6.6 (− 2.5 to 15.7) 0.136
Leakage of pancreatic anastomosis (%) 1 (1.1%) 1 (2.0%) 0.9 (− 3.6 to 5.3) 1.000
Leakage of small intestine and colon (%) – 1 (2.0%) 2.0 (− 1.9 to 5.9) 0.360
VAC therapy (%) 87 (97.8%) 45 (90.0%) − 7.8 (− 16.6 to 1.1) 0.098
Duration of redo-surgery in minutes (IQR) 70 (43–110) 111 (80–181) 0.72 (0.61 to 0.80) < 0.001
Incidence of intestinal fistula until 100 days after OA (%) 16 (18.0%) 11 (22.0%) 4.0 (− 10.0 to 18.0) 0.656
Occurrence of intestinal fistula before OA (%) 7 (7.9%) 4 (8.0%) 0.1 (− 9.2 to 9.5) 1.000
Intestinal fistula during OA treatment (%) 9 (10.1%) 7 (14.0%) 3.9 (− 7.6 to 15.4) 0.582
Type of intestinal fistula (%)
 Small intestine 13 (14.6%) 9 (18.0%) 3.4 (− 9.5 to 16.3) 0.633
 Enteroatmospheric 3 (3.4%) 2 (4.0%) 0.6 (− 6.0 to 7.2) 1.000
In-hospital mortality (%) 20 (22.5%) 9 (18.0%) − 4.5 (− 18.2 to 9.3) 0.665
Reason for mortality (%)
 Cardiopulmonary insufficiency 2 (2.2%) – − 2.2 (− 5.3 to 0.8) 1.000
 Sepsis/multi-organ failure 12 (13.5%) 6 (12.0%) − 1.5 (− 13.0 to 10.0) 1.000
 Underlying disease 3 (3.4%) 2 (4.0%) 0.6 (− 6.0 to 7.2) 0.633
 OtherA 3a (3.4%) 1b (2.0%) − 1.4 (− 6.7 to 4.0) 1.000
Patients requiring intensive care (%) 85 (95.5%) 47 (94.0%) − 1.5 (−9.4 to 6.4) 0.702
 Days at intensive care unit (IQR) 20 (6–36) 11 (6–16) 0.37 (0.27 to 0.46) 0.002
Termination of OA treatment after initiation in days (IQR) 28 (9–63) 3 (0–7) 0.13 (0.06 to 0.19) < 0.001
 Fascia closed (%) 66 (74.2%) 13 (26.0%) − 48.2 (− 63.3 to − 33.0) < 0.001
SSI at discharge (%) 16 (18.0%) 27 (54.0%) 36.0 (20.1 to 52.0) < 0.001
Duration of hospital stay in days (IQR) 66 (33–109) 49 (34–72) 0.40 (0.3 to 0.49) 0.007
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median of 648 days (151–1207)] and 12 patients for VAC-
IPOM [after a median of 269 days (55–454), p = 0.001]. 
Hernia-free survival showed a significant curve separation 
when comparing VAC-IPOM with VAWCM (p = 0.041) 
(Fig. 3).
Mesh‑related complications
SSI at last follow-up did not differ when comparing poly-
propylene-based meshes with polyester-based meshes [n = 9 
(28.1%) vs n = 3 (33.3%), p = 1.000]. A higher but not sig-
nificant incidence of SSI was found when fascial closure was 
not achieved [n = 11 (34.4%)] compared to fascial closure 
[n = 1 (12.5%), p = 0.240]. Partial mesh explantation due to 
persistent SSI was necessary in 4 (9.8%) patients. There was 
no difference in partial mesh explantation when comparing 
polypropylene-based meshes with polyester-based meshes 
(n = 3 polypropylene versus n = 1 polyester mesh, p = 1.000). 
We did not find a difference in incidence of intestinal fistula 
until 100 days after OA (n = 10 polypropylene versus n = 1 
polyester mesh, p = 0.416).
Discussion
The current study shows that VAC-IPOM in patients with 
OA treatment decrease re-operations, duration of hospital 
and ICU stay, and the incidence of incisional hernia, when 
compared with VAWCM, which represents the current 
standard of care.
OA treatment with temporary abdominal closure should 
address three main clinical problems: (1) survival of the 
patient; (2) prevention of short-term complications of the 
abdominal wall; (3) reduction of long-term complications.
To improve survival and to prevent multi-organ injury in 
OA, the initial management of abdominal sepsis includes 
removal of inflammatory ascites [14, 15]. This is mainly 
achieved by vacuum therapy, which is offered by both, VAC-
IPOM and VAWCM and thereby potentially explains the 
comparable in-hospital mortality.
To reduce short-term complications, the integrity of the 
abdominal wall should be restored as soon as hemodynamic 
stabilization and removal of septic foci have been achieved. 
Repetitive abdominal dressings in this setting as required by 
VAWCM are potentially unnecessary or even harmful lead-
ing to a marked increase in duration of stay on ICU.
The fascial closure rate of the current series with 
VAWCM was similar to a previously published meta-
analysis, i.e., 73.1% [3]. However, the fasciae of 25.8% of 
patients using the VAWCM technique were not closed and a 
planned ventral hernia was the consequence, which could be 
prevented by the VAC-IPOM technique. In the VAC-IPOM 
group, fascial closure was not required in the majority of 
patients because this technique was sufficient to stabilize 
the abdominal wall and prevented excessive fascial trac-
tion. Therefore, high tension to achieve fascial closure can 
be avoided.
Intestinal fistula is a putative complication in patients 
with OA and might potentially further complicate the 
clinical course [16]. The current series supports a grow-
ing body of literature showing that the incidence of 
enterocutaneous fistula in the contaminated abdomen is 
not different when compared to a cohort without synthetic, 
intraperitoneal mesh implantation [8, 9, 17–19]. Visceral 
protection with dual-layered meshes seems to be a key 
element in prevention of mesh-related intestinal fistula 
in these patients [20]. Because of this additional barrier 
function, the VAC-IPOM technique also allows bedside 
subcutaneous VAC treatment, avoiding unnecessary 
re-operations.
The frequency of SSI in this population is high and 
may be complicated by chronic mesh infection [21]. 
Even though mesh removal is a putative complication for 
chronic SSI (especially in patients with peritonitis), mesh 
explantation is rarely necessary [22].
At long-term follow-up, incisional hernia is the most 
important complication in patients after OA [23, 24]. Even 
in a series of patients with a very high fascial closure rate 
of 88%, the rate of incisional hernias remained high with 
an incidence of at least 28.6% [25]. These high incidences 
Fig. 1  Re-operations after initiation of open abdomen until discharge
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Table 3  Unadjusted and adjusted effect of mesh-augmentation on important outcome variables
Odds ratios, hazard ratios and incidence risk ratios are shown VAC-IPOM versus VAWCM. Variables with a p value below 0.2 on univariable 
analysis are displayed
Bold values are considered significant (p < 0.05)
95% CI 95% confidence interval; ASA American Society of Anaesthesiology
Unadjusted p Adjusted p
Odds ratio (95% CI) Odds ratio (95% CI)
In-hospital mortality
 VAC-IPOM 0.76 (0.32–1.82) 0.534 0.45 (0.13–1.61) 0.221
 ASA score > 3 2.56 (1.02–6.42) 0.045 3.92 (1.08–14.23) 0.038
 Emergency primary procedure 2.04 (0.88–4.71) 0.097 3.60 (1.13–11.44) 0.030
 Immunosuppressive drugs 4.72 (1.54–14.46) 0.006 5.14 (1.43–18.44) 0.012
Unadjusted p Adjusted p
Odds ratio (95% CI) Odds ratio (95% CI)
Intestinal fistula at 100 days
 VAC-IPOM 1.29 (0.54–3.04) 0.566 2.06 (0.78–5.42) 0.143
 ASA score > 3 0.26 (0.05–1.02) 0.052 0.19 (0.04–0.97) 0.045
 Emergency primary procedure 0.38 (0.15–0.94) 0.035 0.47 (0.18–1.20) 0.114
Unadjusted p Adjusted p
Hazard ratio (95% CI) Hazard ratio (95% CI)
Hernia-free survival
 VAC-IPOM 0.30 (0.09–1.02) 0.055 0.36 (0.10–1.27) 0.114
 Immunosuppressive drugs 3.02 (0.87–10.5) 0.083 2.74 (0.78–9.64) 0.116
 Age 0.97 (0.94–1.00) 0.078 0.97 (0.94–1.01) 0.126
Unadjusted p Adjusted p
Hazard ratio (95% CI) Hazard ratio (95% CI)
Duration of stay on Intensive care unit
 VAC-IPOM 0.52 (0.36–0.77) < 0.001 0.53 (0.36–0.79) 0.002
 Emergency primary procedure 1.26 (0.89–1.78) 0.193 1.29 (0.88–1.89) 0.198
 Immunosuppressive drugs 1.67 (0.97–2.90) 0.066 1.38 (0.79–2.43) 0.257
 Age 1.01 (1.00–1.03) 0.034 1.01 (1.00–1.03) 0.109
 Malignancy 0.67 (0.47–0.95) 0.026 0.77 (0.53–1.13) 0.189
Unadjusted p Adjusted p
Hazard ratio (95% CI) Hazard ratio (95% CI)
Duration of hospital stay
 VAC-IPOM 0.57 (0.38–0.87) 0.008 0.61 (0.40–0.94) 0.024
 Age 1.02 (1.00–1.03) 0.029 1.01 (1.00–1.03) 0.115
 Malignancy 0.74 (0.49–1.01) 0.138 0.86 (0.58–1.30) 0.484
Unadjusted p Adjusted p
Incidence risk ratio (95% CI) Incidence risk ratio (95% CI)
Re-operations during OA treatment
 VAC-IPOM 0.49 (0.41–0.58) < 0.001 0.48 (0.39–0.58) < 0.001
 ASA Score > 3 0.70 (0.57–0.85) < 0.001 1.04 (0.82–1.32) 0.755
 Emergency primary procedure 0.89 (0.78–1.02) 0.090 0.89 (0.76–1.04) 0.134
 Age 0.99 (0.99–0.99) < 0.001 1.00 (0.99–1.00) 0.345
 Malignancy 0.69 (0.60–0.79) < 0.001 0.75 (0.64–0.89) < 0.001
 BMI 1.00 (1.00–1.01) 0.117 1.01 (1.00–1.01) 0.016
 Male gender 0.81 (0.71–0.92) 0.001 0.90 (0.78–1.04) 0.151
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of incisional hernia and the fact that the collagen structure 
is comprised in these patients (Fig. SDC 2) indicates the 
importance of a reinforcement of the abdominal wall. Bio-
logic meshes are an option for the treatment of abdominal 
wall defects in contaminated fields [26]. However, a recent 
meta-analysis revealed that biologic meshes were asso-
ciated with more surgical site complications and hernia 
recurrence compared to synthetic meshes [27]. Therefore, 
usage of biologic meshes for such situations should be 
critically reevaluated [28].
Limitations of this study include its retrospective design 
and the fact that two different centres were compared with 
differences in health care. The fact that both hospitals treat a 
similar number of patients using a comparable surgical spec-
trum, confounding biases should be reduced. Essentially, prior 
to data collection, outcome parameters were pre-defined to 
overcome different definitions. Additionally, the most relevant 
outcome parameters (Mortality, intestinal fistula, fascial clo-
sure, hernia) did not differ compared to other published series 
[3]. Of note, the current series almost exclusively consists of 
non-trauma patients.
Conclusion
In the current study, VAC-IPOM in patients with OA 
decreased re-operations, duration of hospital and ICU 
stay, and the incidence of incisional hernia compared to 
VAWCM. Based on these results, abdominal closure using 
synthetic mesh-augmentation represents a therapeutic 
option in patients undergoing OA treatment.
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